Sandra L Knowles

US Patent:

20200207758, Jul 2, 2020

Filed:

Jun 22, 2018

Appl. No.:

16/621959

Inventors:

Jianming BAO - San Mateo CA, US
Qiaolin DENG - Princeton NJ, US
Melissa EGBERTSON - Ambler PA, US
Ronald FERGUSON, II - Scotch Plains NJ, US
Xiaolei GAO - Bridgewater NJ, US
Scott Timothy HARRISON - Elkins Park PA, US
Sandra L. KNOWLES - Princeton NJ, US
Chunsing LI - Shanghai, CN
Michael Man-Chu LO - Bedminster NJ, US
Zhaoyang MENG - Ambler PA, US
Meng NA - Shanghai, CN
Michael T. RUDD - Collegeville PA, US
Oleg SELYUTIN - West Windsor NJ, US
David M. TELLERS - Lansdale PA, US
Ling TONG - Warren NJ, US
Fengqi ZHANG - Edison NJ, US

Assignee:

Merck Sharp & Dohme Corp. - Rahway NJ

International Classification:

C07D 471/04
C07D 401/14
C07D 401/04
C07D 413/14
C07D 405/14
C07D 491/048
C07D 498/04

Abstract:

The present invention is directed to pyrazol-4-yl-pyridine compounds which are allosteric modulators of the M4 muscarinic acetylcholine receptor. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which M4 muscarinic acetylcholine receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which M4 muscarinic acetylcholine receptors are involved.

US Patent:

20200069671, Mar 5, 2020

Filed:

Nov 5, 2019

Appl. No.:

16/674546

Inventors:

- Rahway NJ, US
Jianming Bao - South San Francisco CA, US
Melissa Egbertson - Ambler PA, US
Xiaolei Gao - Bridgewater NJ, US
Scott T. Harrison - Elkins Park PA, US
Sandra L. Knowles - Princeton NJ, US
Chunsing Li - Shanghai, CN
Michael Man-Chu Lo - Bedminster NJ, US
Zhaoyang Meng - Ambler PA, US
Michael T. Rudd - Collegeville PA, US
Oleg B. Selyutin - West Windsor NJ, US
David M. Tellers - Lansdale PA, US
Ling Tong - Warren NJ, US
Jenny Miu-Chun Wai - Harleysville PA, US

Assignee:

Merck Sharp & Dohme Corp. - Rahway NJ
MSD R & D (China) Co., Ltd. - Shanghai

International Classification:

A61K 31/4439
A61P 25/28
A61P 25/18
A61P 25/16
A61K 31/437
C07D 401/14
C07D 405/14
C07D 471/04

Abstract:

The present invention is directed to pyrazol-4-yl-pyridine compounds which are allosteric modulators of the M4 muscarinic acetylcholine receptor. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which M4 muscarinic acetylcholine receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which M4 muscarinic acetylcholine receptors are involved.

US Patent:

20190000824, Jan 3, 2019

Filed:

Dec 19, 2016

Appl. No.:

16/062500

Inventors:

- Rahway NJ, US
Jianming Bao - South San Francisco CA, US
Melissa Egbertson - Ambler PA, US
Xiaolei Gao - Bridgewater NJ, US
Scott T. Harrison - Elkins Park PA, US
Sandra L. Knowles - Princeton NJ, US
Chunsing Li - Shanghai, CN
Michael Man-Chu Lo - Bedminster NJ, US
Zhaoyang Meng - Ambler PA, US
Michael T. Rudd - Collegeville PA, US
Oleg B. Selyutin - West Windsor NJ, US
David M. Tellers - Lansdale PA, US
Ling Tong - Warren NJ, US
Jenny Miu-Chun Wai - Harleysville PA, US

Assignee:

Merck Sharp & Dohme Corp. - Rahway NJ

International Classification:

A61K 31/4439
A61K 31/437
A61P 25/16
A61P 25/18
A61P 25/28

Abstract:

The present invention is directed to pyrazol-4-yl-pyridine compounds which are allosteric modulators of the M4 muscarinic acetylcholine receptor. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which M4 muscarinic acetylcholine 5 receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which M4 muscarinic acetylcholine receptors are involved.